.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Chubb
Novartis
UBS
Teva
Boehringer Ingelheim
Farmers Insurance
US Army
Covington
Mallinckrodt

Generated: July 22, 2017

DrugPatentWatch Database Preview

Pfizer Ireland Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER IRELAND, and what generic alternatives to PFIZER IRELAND drugs are available?

PFIZER IRELAND has one approved drug.

There are two US patents protecting PFIZER IRELAND drugs.

There are one hundred and forty-seven patent family members on PFIZER IRELAND drugs in forty-six countries.

Summary for Applicant: Pfizer Ireland

Patents:2
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002ABRXYesYes6,110,940► Subscribe ► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002ABRXYesNo5,545,644► SubscribeYY ► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002ABRXYesYes5,545,644► SubscribeYY ► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002ABRXYesNo6,110,940► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pfizer Ireland

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 20025,545,644► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 20025,545,644► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PFIZER IRELAND drugs

Drugname Dosage Strength Tradename Submissiondate
eletriptan hydrobromide
Tablets20 mg and 40 mg
RELPAX
3/29/2010

Non-Orange Book Patents for Pfizer Ireland

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,380,226 Salts of an anti-migraine indole derivatives► Subscribe
5,559,129 Indole derivatives► Subscribe
5,578,612 Indole derivatives► Subscribe
5,607,951 Indole derivatives► Subscribe
5,559,246 Indole derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pfizer Ireland Drugs

Country Document Number Estimated Expiration
Singapore54270► Subscribe
Mexico9701538► Subscribe
China1515252► Subscribe
Finland113768► Subscribe
Australia8950491► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pfizer Ireland Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0013France► SubscribePRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214
C/GB01/023United Kingdom► SubscribePRODUCT NAME: ELETRIPTAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE HYDROBROMIDE SALT; REGISTERED: CH 55218 01 20001214; CH 52218 02 20001214; CH 52218 03 20001214; UK PL 00057/0452 20010212; UK PL 00057/0453 20010212; UK PL 00057/0454 20010212
/2001Austria► SubscribePRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214
0592438/01Switzerland► SubscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Argus Health
Mallinckrodt
Johnson and Johnson
Harvard Business School
Medtronic
Dow
Queensland Health
Farmers Insurance
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot